Work

Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report

Year: 2026

Type: article

Abstract: B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations are rare (1-2%) in invasive mucinous adenocarcinoma (IMA). The therapeutic effect of dabrafenib combined with trametinib in IMA with BRAF mutations remains unknown. An 82-year-old man with a BRAF V600E mutation was diagnosed with mixed invasive mucinous and nonmucinous adenocarcinoma of the lung (cT4N1M1a, stage IVA) and he was treated with dabrafenib plus trametinib. The treatment effect continued for 14 months, suggesting that combined dabrafenib and trametinib as targeted therapy is a potential treatment option for BRAF V600E mutation-positive mixed invasive mucinous and nonmucinous adenocarcinoma of the lung.

Source: Internal Medicine

DOI: 10.2169/internalmedicine.7575-26

Authors: Yosuke Kakiuchi, Miyu Imai

Institutions: Japan Community Healthcare Organization, Hitoyoshi Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7167895458

FWCI:

Cites: 14

Cited by:

Related to: 10